Scholar Rock, Inc.   Report issue

For profit Phase 1 Phase 3
Founded: Cambridge MA United States (2012)

Organization Overview

First Clinical Trial
2019
NCT03921528
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Scholar Rock, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

srk-015 (3 trials)

Drugs in Phase 1 Trials (1)

SRK-181 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 2)

Muscular Atrophy (Phase 2)

Muscular Atrophy, Spinal (Phase 2)

Neuromuscular Diseases (Phase 2)

Neuromuscular Manifestations (Phase 2)

Spinal Muscular Atrophies of Childhood (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2